Alimera Sciences, Inc. (ALIM) News
Filter ALIM News Items
ALIM News Results
|Loading, please wait...|
Latest ALIM News From Around the Web
Below are the latest news stories about Alimera Sciences Inc that investors may wish to consider to help them evaluate ALIM as an investment opportunity.
Diabetic Retinopathy Market 2021 Comprehensive Insights - Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides
The Diabetic Retinopathy Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Diabetic Retinopathy market. It particularly sheds light on market fluctuations, pricing structure,
Novel Ocular Drug Delivery Devices Market Business Growth and Opportunities with Valeant Pharmaceuticals, Ocular Therapeutix, Graybug Vision, EyeGate Pharma, Clearside Biomedical, Alimera Sciences, EyeGate Pharma, Envisia Therapeutics, Allergan
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer., announces today that Chief Executive Officer Rick Eiswirth will present at the 23 rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13 15, 2021.
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN ® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI). Pricing and reimbursement approval was sought and secured by Alimeras distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is currently in the launch phase in Belgium.
Insights on the Diabetic Retinopathy Global Market to 2026 - Featuring Alimera Sciences, Allergan and Bayer Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. Looking forward, the publisher expects the market to grow at a CAGR of 5.6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indi
Alimera Sciences, Inc. (NASDAQ: ALIM) Q2 2021 earnings call dated Aug. 13, 2021 Presentation: Operator Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera  The post Alimera Sciences, Inc. (ALIM) Q2 2021 Earnings Call Transcript first appeared on AlphaStreet .
ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
Joining me today from Alimera's leadership team are Rick Eiswirth, President and Chief Executive Officer; and Phil Jones, Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address Alimera's expectations for future performance or operational results.
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern TimeATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report second quarter 2021 financial results on Friday, August 13, 2021, prior to the market open. Management will host a conference